ACell, Inc., a regenerative medicine company focused on the development, manufacturing and commercialization of surgical and wound management products, began construction on expansion of its Lafayette, Indiana manufacturing facility.

The 14,000 square-foot addition to its current building will increase scalability and efficiency of ACell's day-to-day operations and is expected to be completed in late 2014, the company said. With the expansion, the total manufacturing space will exceed 42,000 square feet.

"The significant growth of our business driven by continued physician adoption of MatriStem has driven us to expand capacity at our Lafayette facility by roughly 50 percent," said Rodney Bosley, ACell President and Chief Operating Officer. "Our Indiana facility is currently capable of producing all of our 510(k) cleared products from raw material processing through final packaging. This expansion will provide us with additional end-to-end manufacturing capabilities that we believe will support our growth for several years to come."

ACell manufactures its MatriStem products in facilities located in Lafayette, Indiana and Columbia, Maryland using a complex and highly specialized process, requiring precision and expertise to address various technical, engineering and regulatory challenges. The Lafayette facility processes all of the material used in MatriStem products and manufactures the majority of ACell's products.

"As an integral part of the Lafayette community, ACell offers an opportunity to help stimulate the local economy, and we are proud to support the Company as they expand their facility with the goal of transforming the standard of medical care and improving the quality of life of patients who are treated with their devices," said City of Lafayette Mayor Tony Roswarski.